Pre-exposure prophylaxis for HIV prevention (English Wikipedia)

"Pre-Exposure Prophylaxis (PrEP)". AFAO.org.au. Australian Federation of AIDS Organizations. Retrieved 15 December 2017.
"PrEP". Australian Federation of AIDS Organisations. Retrieved 31 July 2020.

aidshealth.org

Kenslea G (11 April 2019). "41 HIV and PrEP Patients File California Personal Injury Lawsuit Over Gilead's TDF-Based Drugs". AIDS Healthcare Foundation (AHF). Retrieved 9 December 2019.
"AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs". AIDS Healthcare Foundation (AHF). 16 July 2019. Retrieved 10 December 2019.

aidsmap.com

"PrEP does not raise lipids or alter body fat, safety study finds". Retrieved 16 February 2018.
Cairns G (22 February 2017). "STI rates in PrEP users very high, but evidence that PrEP increases them is inconclusive". AIDSMap.com. Retrieved 15 December 2017.
Highleyman L (24 June 2016). "PrEP use is rising fast in US, but large racial disparities remain". AIDSMap.org. Retrieved 15 December 2017.

aidsmeds.com

"Top Stories: Poor Adherence Crippled PrEP Efficacy in Women's Study - by Tim Horn". aidsmeds.com. Archived from the original on 24 December 2015. Retrieved 23 December 2015.
"Top Stories: Failed VOICE PrEP Trial Failed to Preempt Lies About Adherence". aidsmeds.com. Archived from the original on 24 December 2015. Retrieved 23 December 2015.

avac.org

"DISCOVER Trial Factsheet". AVAC. 6 December 2016. Archived from the original on 17 May 2022. Retrieved 13 February 2019.

bbc.com

Gallagher J (3 August 2017). "Prep: HIV 'game-changer' to reach NHS in England from September". BBC News Online. Retrieved 15 December 2017.

bhiva.org

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018

ca.gov

leginfo.legislature.ca.gov

"Bill Text - SB-159 HIV: preexposure and postexposure prophylaxis". leginfo.legislature.ca.gov. Retrieved 31 July 2020.

cdc.gov

Centers for Disease Control and Prevention: US Public Health Service (2021). "Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 Update: a clinical practice guideline" (PDF). Archived (PDF) from the original on 14 August 2023. Retrieved 23 August 2023.
US Public Health Service. "Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014" (PDF). Centers for Disease Control and Prevention (CDC). Archived from the original (PDF) on 11 April 2018. Retrieved 15 December 2017.
"Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update Clinical Practice Guideline" (PDF). Centers for Disease Control and Prevention.
"Pre-Exposure Prophylaxis (PrEP) | HIV Risk and Prevention | HIV/AIDS | CDC". www.cdc.gov. 4 June 2020. Retrieved 30 July 2020.
"Bangkok Tenofovir Study: PrEP for HIV prevention among people who inject drugs" (PDF). Centers for Disease Control and Prevention (CDC). Retrieved 23 December 2015.

npin.cdc.gov

"NPIN PrEP Provider Data and Locator Widget". Centers for Disease Control and Prevention. Archived from the original on 31 August 2022. Retrieved 31 July 2020.

doi.org

Riddell J, Amico KR, Mayer KH (March 2018). "HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. doi:10.1001/jama.2018.1917. PMID 29584848. S2CID 205096939.
Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. PMID 31184746.
Mayer KH, Allan-Blitz LT (December 2019). "PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention". Journal of Acquired Immune Deficiency Syndromes. 82 (2): S113–S117. doi:10.1097/QAI.0000000000002169. PMC 6830954. PMID 31658197.
Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. (January 2001). "Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. S2CID 34714025.
Desai M, Field N, Grant R, McCormack S (December 2017). "Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. (December 2015). "On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection". The New England Journal of Medicine. 373 (23): 2237–46. doi:10.1056/NEJMoa1506273. PMID 26624850.
Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R (August 2019). "Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. doi:10.1007/s40265-019-01143-8. PMID 31309457. S2CID 196811170.
Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. (December 2016). "Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714.
Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, et al. (April 2020). "HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN (April 2017). "Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
Pereira M, de Castro CT, Magno L, Oliveira Td, Gomes FS, Neves FM, et al. (2023). "Adverse effects of daily oral pre-exposure prophylaxis in men who have sex with men and transgender women: a systematic review and meta-analysis". Cadernos de Saúde Pública. 39 (Suppl 1): e00089522. doi:10.1590/0102-311XEN089522. ISSN 0102-311X. PMC 10712916. PMID 38088646.
Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC (March 2010). "Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. (13 March 2014). "Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530.
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. (25 July 2020). "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial". The Lancet. 396 (10246): 239–254. doi:10.1016/S0140-6736(20)31065-5. PMC 9665936. PMID 32711800.
Wise J (6 June 2018). "Pre-exposure prophylaxis may increase risky behaviour when introduced, study finds". BMJ: 361. doi:10.1136/bmj.k2514. S2CID 46965502.
O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. (May 2022). "Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations". BMJ Open. 12 (5): e048478. doi:10.1136/bmjopen-2020-048478. ISSN 2044-6055. PMC 9096492. PMID 35545381.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/S2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K (3 June 2021). "Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies". AIDS Care. 33 (6): 697–705. doi:10.1080/09540121.2020.1778628. ISSN 0954-0121. PMID 32530302. S2CID 219606855.
Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. (May 2017). "Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature". AIDS and Behavior. 21 (5): 1325–1335. doi:10.1007/s10461-016-1627-z. PMC 5378753. PMID 27900502.
Jin G, Shi H, Du J, Guo H, Yuan G, Yang H, et al. (1 December 2023). "Pre-Exposure Prophylaxis Care Continuum for HIV Risk Populations: An Umbrella Review of Systematic Reviews and Meta-Analyses". AIDS Patient Care and STDs. 37 (12): 583–615. doi:10.1089/apc.2023.0158. ISSN 1087-2914. PMID 38011347. S2CID 265463138.
Dubov A, Galbo P, Altice F, Fraenkel L (August 2018). "Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study". American Journal of Men's Health. 12 (6): 1843–1854. doi:10.1177/1557988318797437. PMC 6199453. PMID 30160195.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C (March 2013). "Worldwide burden of HIV in transgender women: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 13 (3): 214–22. doi:10.1016/S1473-3099(12)70315-8. PMID 23260128.
Pacífico de Carvalho N, Mendicino CC, Cândido RC, Alecrim DJ, Menezes de Pádua CA (October 2019). "HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review". AIDS Care. 31 (10): 1234–1240. doi:10.1080/09540121.2019.1612014. PMID 31043069. S2CID 143425925.
Conley C, Johnson R, Bond K, Brem S, Salas J, Randolph S (January 2022). "US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review". Women's Health. 18: 174550572211030. doi:10.1177/17455057221103098. ISSN 1745-5057. PMC 9201306. PMID 35699104.
Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE, et al. (1 September 2019). "Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review". Journal of Women's Health. 28 (9): 1272–1285. doi:10.1089/jwh.2018.7353. ISSN 1540-9996. PMID 31180253. S2CID 182949977.
Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. (January 2008). "Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice". PLOS Medicine. 5 (1): e16. doi:10.1371/journal.pmed.0050016. PMC 2194746. PMID 18198941.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. (December 2010). "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men". The New England Journal of Medicine. 363 (27): 2587–99. doi:10.1056/NEJMoa1011205. PMC 3079639. PMID 21091279.
Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. (October 2011). "Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication". Cell Host & Microbe. 10 (4): 379–89. doi:10.1016/j.chom.2011.08.015. PMC 3201796. PMID 22018238.
Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, et al. (May 2014). "Adherence in the CAPRISA 004 tenofovir gel microbicide trial". AIDS and Behavior. 18 (5): 811–9. doi:10.1007/s10461-014-0751-x. PMC 4017080. PMID 24643315.
Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. (August 2012). "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women". The New England Journal of Medicine. 367 (5): 399–410. doi:10.1056/NEJMoa1108524. PMC 3770474. PMID 22784037.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. (August 2012). "Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana". The New England Journal of Medicine. 367 (5): 423–34. doi:10.1056/NEJMoa1110711. PMID 22784038.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. (June 2013). "Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial". Lancet. 381 (9883): 2083–90. doi:10.1016/S0140-6736(13)61127-7. PMID 23769234. S2CID 5831642.
Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, et al. (March 2016). "An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis". Trials. 17: 163. doi:10.1186/s13063-016-1286-4. PMC 4806447. PMID 27013513.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/s2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Freeborn K, Portillo CJ (September 2018). "Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review". Journal of Clinical Nursing. 27 (17–18): 3254–3265. doi:10.1111/jocn.13990. PMC 5797507. PMID 28771856.

europa.eu

ema.europa.eu

"First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU". European Medicines Agency (EMA) (Press release). 22 July 2016. Retrieved 12 January 2017.

fda.gov

"FDA approves the second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic". U.S. Food and Drug Administration (FDA) (Press release). 3 October 2019. Archived from the original on 10 October 2019. Retrieved 10 October 2019. This article incorporates text from this source, which is in the public domain.
"FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention". U.S. Food and Drug Administration. 20 December 2021. Retrieved 20 April 2022.

gaystarnews.com

"Korea has just approved PrEP but who can afford it at that price?". Gay Star News. 21 February 2018. Archived from the original on 5 January 2021. Retrieved 21 February 2018.

gaytimes.com

"PrEP slutshaming is still alive and well – and it's harming us all". 3 May 2024. Retrieved 15 May 2024.

getting2zerosd.com

"Getting To Zero | Eliminate all new HIV infections in San Diego County within 10 years". Getting To Zero. Retrieved 3 August 2020.

gettingtozeroct.org

"Getting to Zero CT – Zero HIV Infections. Zero HIV Stigma. Zero HIV Deaths". Retrieved 3 August 2020.

gettingtozeroma.org

"Getting To Zero MA – Welcome to Zero HIV Stigma, Zero HIV Deaths, Zero HIV Infections". www.gettingtozeroma.org. Archived from the original on 5 October 2022. Retrieved 3 August 2020.

gettingtozeroscc.org

"Getting to Zero: Silicon Valley | Santa Clara County". Getting to Zero Silicon Valley. Retrieved 3 August 2020.

gettingtozerosf.org

"About HIV and San Francisco". Getting to Zero. San Francisco Department of Public Health. Retrieved 15 December 2017.

gilead.com

Gilead. "U.S. Food and Drug Administration Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV". Gilead. Retrieved 15 December 2017.
"Pre-Exposure Prophylaxis (PrEP) for HIV Prevention" (PDF). Gilead Sciences Policy Position. Gilead Sciences. Retrieved 15 December 2017.

gileadadvancingaccess.com

"Gilead Advancing Access® Co-pay Coupon Program". www.gileadadvancingaccess.com. Retrieved 4 August 2020.

goodrx.com

"Truvada for HIV PrEP: How Much It Costs and How to Save - GoodRx". The GoodRx Prescription Savings Blog. 29 August 2018. Retrieved 4 August 2020.

gtzillinois.hiv

"Home". gtzillinois.hiv. Retrieved 3 August 2020.

handle.net

hdl.handle.net

Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/S2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/s2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.

harvard.edu

ui.adsabs.harvard.edu

Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. (13 March 2014). "Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530.

healio.com

"Truvada as HIV PrEP not associated with net fat increase". www.healio.com. Retrieved 16 February 2018.

health.gov.au

"Securing supply of PrEP". Department of Health and Aged Care, ministerial press releases. Retrieved 1 October 2024.

hiv.gov

"Pre-Exposure Prophylaxis". HIV.gov. 3 December 2019. Retrieved 3 August 2020.
"Pre-Exposure Prophylaxis". HIV.gov. 2019. Retrieved 3 August 2020.

hivequal.org

Heitz D (23 February 2016). "The Possibility of PrEP that's Not Truvada". HIVEqual. Archived from the original on 15 December 2017. Retrieved 15 December 2017.
Heitz D (19 October 2015). "PrEP You Don't Swallow: The Future of Anal HIV Prevention". HIVEqual.com. Archived from the original on 1 April 2019. Retrieved 15 December 2017.

hptn.org

"HPTN 083 FAQ" (PDF). HPTN. 17 May 2020.

iprexnews.com

"Adherence Indicators and PrEP Drug Levels in the iPrEx Study" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 23 December 2015.

latimes.com

Petersen M (29 May 2016). "A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner". Los Angeles Times. Retrieved 9 December 2019.

liebertpub.com

Jin G, Shi H, Du J, Guo H, Yuan G, Yang H, et al. (1 December 2023). "Pre-Exposure Prophylaxis Care Continuum for HIV Risk Populations: An Umbrella Review of Systematic Reviews and Meta-Analyses". AIDS Patient Care and STDs. 37 (12): 583–615. doi:10.1089/apc.2023.0158. ISSN 1087-2914. PMID 38011347. S2CID 265463138.
Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE, et al. (1 September 2019). "Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review". Journal of Women's Health. 28 (9): 1272–1285. doi:10.1089/jwh.2018.7353. ISSN 1540-9996. PMID 31180253. S2CID 182949977.

medpagetoday.com

Broder M (11 September 2017). "Does PrEP Lead to Riskier Behavior?". MedPageToday. Retrieved 10 October 2019.

medscape.com

Brooks M (22 July 2016). "Truvada Recommended as First Drug for HIV PrEP in Europe". Medscape. Retrieved 15 December 2017.

modernhealthcare.com

Johnson SR (30 November 2018). "Clinicians warn HIV prevention drug use can lead to risky behavior". Modern Healthcare. Retrieved 10 October 2019.

nbcnews.com

"Generic HIV prevention drug coming in 2020, Gilead says". NBC News. 8 May 2019. Retrieved 4 August 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Riddell J, Amico KR, Mayer KH (March 2018). "HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. doi:10.1001/jama.2018.1917. PMID 29584848. S2CID 205096939.
Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. PMID 31184746.
Mayer KH, Allan-Blitz LT (December 2019). "PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention". Journal of Acquired Immune Deficiency Syndromes. 82 (2): S113–S117. doi:10.1097/QAI.0000000000002169. PMC 6830954. PMID 31658197.
Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. (January 2001). "Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. S2CID 34714025.
Desai M, Field N, Grant R, McCormack S (December 2017). "Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. (December 2015). "On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection". The New England Journal of Medicine. 373 (23): 2237–46. doi:10.1056/NEJMoa1506273. PMID 26624850.
Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention. WHO Guidelines Approved by the Guidelines Review Committee. World Health Organization. 2022. PMID 36417549.
Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R (August 2019). "Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. doi:10.1007/s40265-019-01143-8. PMID 31309457. S2CID 196811170.
Celum CL (December 2011). "HIV preexposure prophylaxis: new data and potential use". Topics in Antiviral Medicine. 19 (5): 181–5. PMC 6148898. PMID 22298887.
Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. (December 2016). "Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714.
Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, et al. (April 2020). "HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN (April 2017). "Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
Pereira M, de Castro CT, Magno L, Oliveira Td, Gomes FS, Neves FM, et al. (2023). "Adverse effects of daily oral pre-exposure prophylaxis in men who have sex with men and transgender women: a systematic review and meta-analysis". Cadernos de Saúde Pública. 39 (Suppl 1): e00089522. doi:10.1590/0102-311XEN089522. ISSN 0102-311X. PMC 10712916. PMID 38088646.
Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC (March 2010). "Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. (13 March 2014). "Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530.
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. (25 July 2020). "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial". The Lancet. 396 (10246): 239–254. doi:10.1016/S0140-6736(20)31065-5. PMC 9665936. PMID 32711800.
O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. (May 2022). "Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations". BMJ Open. 12 (5): e048478. doi:10.1136/bmjopen-2020-048478. ISSN 2044-6055. PMC 9096492. PMID 35545381.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/S2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K (3 June 2021). "Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies". AIDS Care. 33 (6): 697–705. doi:10.1080/09540121.2020.1778628. ISSN 0954-0121. PMID 32530302. S2CID 219606855.
Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. (May 2017). "Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature". AIDS and Behavior. 21 (5): 1325–1335. doi:10.1007/s10461-016-1627-z. PMC 5378753. PMID 27900502.
Jin G, Shi H, Du J, Guo H, Yuan G, Yang H, et al. (1 December 2023). "Pre-Exposure Prophylaxis Care Continuum for HIV Risk Populations: An Umbrella Review of Systematic Reviews and Meta-Analyses". AIDS Patient Care and STDs. 37 (12): 583–615. doi:10.1089/apc.2023.0158. ISSN 1087-2914. PMID 38011347. S2CID 265463138.
Dubov A, Galbo P, Altice F, Fraenkel L (August 2018). "Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study". American Journal of Men's Health. 12 (6): 1843–1854. doi:10.1177/1557988318797437. PMC 6199453. PMID 30160195.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C (March 2013). "Worldwide burden of HIV in transgender women: a systematic review and meta-analysis". The Lancet. Infectious Diseases. 13 (3): 214–22. doi:10.1016/S1473-3099(12)70315-8. PMID 23260128.
Pacífico de Carvalho N, Mendicino CC, Cândido RC, Alecrim DJ, Menezes de Pádua CA (October 2019). "HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review". AIDS Care. 31 (10): 1234–1240. doi:10.1080/09540121.2019.1612014. PMID 31043069. S2CID 143425925.
Conley C, Johnson R, Bond K, Brem S, Salas J, Randolph S (January 2022). "US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review". Women's Health. 18: 174550572211030. doi:10.1177/17455057221103098. ISSN 1745-5057. PMC 9201306. PMID 35699104.
Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE, et al. (1 September 2019). "Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review". Journal of Women's Health. 28 (9): 1272–1285. doi:10.1089/jwh.2018.7353. ISSN 1540-9996. PMID 31180253. S2CID 182949977.
Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. (January 2008). "Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice". PLOS Medicine. 5 (1): e16. doi:10.1371/journal.pmed.0050016. PMC 2194746. PMID 18198941.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. (December 2010). "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men". The New England Journal of Medicine. 363 (27): 2587–99. doi:10.1056/NEJMoa1011205. PMC 3079639. PMID 21091279.
Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. (October 2011). "Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication". Cell Host & Microbe. 10 (4): 379–89. doi:10.1016/j.chom.2011.08.015. PMC 3201796. PMID 22018238.
Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, et al. (May 2014). "Adherence in the CAPRISA 004 tenofovir gel microbicide trial". AIDS and Behavior. 18 (5): 811–9. doi:10.1007/s10461-014-0751-x. PMC 4017080. PMID 24643315.
Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. (August 2012). "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women". The New England Journal of Medicine. 367 (5): 399–410. doi:10.1056/NEJMoa1108524. PMC 3770474. PMID 22784037.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. (August 2012). "Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana". The New England Journal of Medicine. 367 (5): 423–34. doi:10.1056/NEJMoa1110711. PMID 22784038.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. (June 2013). "Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial". Lancet. 381 (9883): 2083–90. doi:10.1016/S0140-6736(13)61127-7. PMID 23769234. S2CID 5831642.
Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, et al. (March 2016). "An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis". Trials. 17: 163. doi:10.1186/s13063-016-1286-4. PMC 4806447. PMID 27013513.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/s2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Freeborn K, Portillo CJ (September 2018). "Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review". Journal of Clinical Nursing. 27 (17–18): 3254–3265. doi:10.1111/jocn.13990. PMC 5797507. PMID 28771856.

ncbi.nlm.nih.gov

Mayer KH, Allan-Blitz LT (December 2019). "PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention". Journal of Acquired Immune Deficiency Syndromes. 82 (2): S113–S117. doi:10.1097/QAI.0000000000002169. PMC 6830954. PMID 31658197.
Desai M, Field N, Grant R, McCormack S (December 2017). "Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention. WHO Guidelines Approved by the Guidelines Review Committee. World Health Organization. 2022. PMID 36417549.
Celum CL (December 2011). "HIV preexposure prophylaxis: new data and potential use". Topics in Antiviral Medicine. 19 (5): 181–5. PMC 6148898. PMID 22298887.
Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. (December 2016). "Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714.
Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, et al. (April 2020). "HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN (April 2017). "Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
Pereira M, de Castro CT, Magno L, Oliveira Td, Gomes FS, Neves FM, et al. (2023). "Adverse effects of daily oral pre-exposure prophylaxis in men who have sex with men and transgender women: a systematic review and meta-analysis". Cadernos de Saúde Pública. 39 (Suppl 1): e00089522. doi:10.1590/0102-311XEN089522. ISSN 0102-311X. PMC 10712916. PMID 38088646.
Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC (March 2010). "Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. (13 March 2014). "Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530.
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. (25 July 2020). "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial". The Lancet. 396 (10246): 239–254. doi:10.1016/S0140-6736(20)31065-5. PMC 9665936. PMID 32711800.
O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. (May 2022). "Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations". BMJ Open. 12 (5): e048478. doi:10.1136/bmjopen-2020-048478. ISSN 2044-6055. PMC 9096492. PMID 35545381.
Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. (May 2017). "Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature". AIDS and Behavior. 21 (5): 1325–1335. doi:10.1007/s10461-016-1627-z. PMC 5378753. PMID 27900502.
Dubov A, Galbo P, Altice F, Fraenkel L (August 2018). "Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study". American Journal of Men's Health. 12 (6): 1843–1854. doi:10.1177/1557988318797437. PMC 6199453. PMID 30160195.
Conley C, Johnson R, Bond K, Brem S, Salas J, Randolph S (January 2022). "US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review". Women's Health. 18: 174550572211030. doi:10.1177/17455057221103098. ISSN 1745-5057. PMC 9201306. PMID 35699104.
Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, et al. (January 2008). "Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice". PLOS Medicine. 5 (1): e16. doi:10.1371/journal.pmed.0050016. PMC 2194746. PMID 18198941.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. (December 2010). "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men". The New England Journal of Medicine. 363 (27): 2587–99. doi:10.1056/NEJMoa1011205. PMC 3079639. PMID 21091279.
Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. (October 2011). "Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication". Cell Host & Microbe. 10 (4): 379–89. doi:10.1016/j.chom.2011.08.015. PMC 3201796. PMID 22018238.
Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, et al. (May 2014). "Adherence in the CAPRISA 004 tenofovir gel microbicide trial". AIDS and Behavior. 18 (5): 811–9. doi:10.1007/s10461-014-0751-x. PMC 4017080. PMID 24643315.
Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC 3266126. PMID 22156901.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. (August 2012). "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women". The New England Journal of Medicine. 367 (5): 399–410. doi:10.1056/NEJMoa1108524. PMC 3770474. PMID 22784037.
Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, et al. (March 2016). "An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis". Trials. 17: 163. doi:10.1186/s13063-016-1286-4. PMC 4806447. PMID 27013513.
Freeborn K, Portillo CJ (September 2018). "Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review". Journal of Clinical Nursing. 27 (17–18): 3254–3265. doi:10.1111/jocn.13990. PMC 5797507. PMID 28771856.

dailymed.nlm.nih.gov

"Truvada- emtricitabine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 9 December 2019.
"Descovy- emtricitabine and tenofovir alafenamide tablet". DailyMed. Retrieved 3 August 2020.

nih.gov

"Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy". National Institutes of Health (NIH). 23 July 2024. Retrieved 30 July 2024.

ny.gov

health.ny.gov

New York State Department of Public Health. "Ending the AIDS Epidemic in New York State". New York State Department of Public Health. Retrieved 15 December 2017.

nytimes.com

McNeil Jr DG (3 December 2019). "200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs". The New York Times. Retrieved 10 December 2019.
Glazek C (26 April 2017). "The C.E.O. of H.I.V." The New York Times Magazine. Retrieved 15 December 2017.

pharmacytimes.com

"Long-Acting Injectable Form of Cabotegravir Safe for HIV Prevention in Pregnant Cisgender Women". Pharmacy Times. 29 July 2024. Retrieved 30 July 2024.

positivelyaware.com

Nelson G (22 March 2017). "Truvada". Positively Aware. Retrieved 4 August 2020.

poz.com

Ryan B (16 February 2017). "PrEP Fails in a Third Man, But This Time HIV Drug Resistance Is Not to Blame". Poz. Retrieved 15 December 2017.
"Changes to Your Face and Body (Lipodystrophy & Wasting)". Poz. Retrieved 16 February 2018.
"Canada and Israel OK Truvada as PrEP to Prevent HIV". Poz. 1 March 2016. Retrieved 12 January 2017.
Straube T (9 May 2019). "Generic PrEP to Arrive in September 2020, but Will Big Savings Follow?". POZ. Retrieved 4 August 2020.

prepster.info

"Prepster". Retrieved 9 May 2024.

prepwatch.org

"Oral PrEP TDF/FTC". PrEPWatch. 17 February 2023. Retrieved 23 August 2023.
"National Policies and Guidelines for PrEP". PrEP Watch. Archived from the original on 8 December 2018. Retrieved 5 December 2017.

semanticscholar.org

api.semanticscholar.org

Riddell J, Amico KR, Mayer KH (March 2018). "HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. doi:10.1001/jama.2018.1917. PMID 29584848. S2CID 205096939.
Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. (January 2001). "Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. S2CID 34714025.
Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R (August 2019). "Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. doi:10.1007/s40265-019-01143-8. PMID 31309457. S2CID 196811170.
Wise J (6 June 2018). "Pre-exposure prophylaxis may increase risky behaviour when introduced, study finds". BMJ: 361. doi:10.1136/bmj.k2514. S2CID 46965502.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/S2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.
Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K (3 June 2021). "Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies". AIDS Care. 33 (6): 697–705. doi:10.1080/09540121.2020.1778628. ISSN 0954-0121. PMID 32530302. S2CID 219606855.
Jin G, Shi H, Du J, Guo H, Yuan G, Yang H, et al. (1 December 2023). "Pre-Exposure Prophylaxis Care Continuum for HIV Risk Populations: An Umbrella Review of Systematic Reviews and Meta-Analyses". AIDS Patient Care and STDs. 37 (12): 583–615. doi:10.1089/apc.2023.0158. ISSN 1087-2914. PMID 38011347. S2CID 265463138.
Pacífico de Carvalho N, Mendicino CC, Cândido RC, Alecrim DJ, Menezes de Pádua CA (October 2019). "HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review". AIDS Care. 31 (10): 1234–1240. doi:10.1080/09540121.2019.1612014. PMID 31043069. S2CID 143425925.
Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE, et al. (1 September 2019). "Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review". Journal of Women's Health. 28 (9): 1272–1285. doi:10.1089/jwh.2018.7353. ISSN 1540-9996. PMID 31180253. S2CID 182949977.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. (June 2013). "Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial". Lancet. 381 (9883): 2083–90. doi:10.1016/S0140-6736(13)61127-7. PMID 23769234. S2CID 5831642.
Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. (August 2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. doi:10.1016/s2352-3018(18)30072-9. hdl:1874/377504. PMID 29885813. S2CID 47015652.

sfaf.org

"New research at CROI 2016: How PrEP changes kidney function". San Francisco AIDS Foundation. 8 March 2016. Retrieved 3 August 2020.
"Resource: Side-by-side comparison: Truvada and Descovy for PrEP". San Francisco AIDS Foundation. Retrieved 3 August 2020.

sfgate.com

Allday E (15 September 2017). "Aggressive prevention pays off as new HIV infections in SF hit a record low". San Francisco Chronicle. Retrieved 15 December 2017.

starobserver.com.au

"Norway becomes first country to offer free PrEP - Star Observer". starobserver.com.au. 21 October 2016. Retrieved 12 January 2017.

tandfonline.com

Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K (3 June 2021). "Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies". AIDS Care. 33 (6): 697–705. doi:10.1080/09540121.2020.1778628. ISSN 0954-0121. PMID 32530302. S2CID 219606855.

thebody.com

Gay Men's Health Crisis (8 August 2016). "GMHC Launches PrEP Ad Campaign in New York City Bus Shelters". Gay Men's Health Crisis. Retrieved 15 December 2017.